Neovasculgen
Sponsors
Artgen Biotech
Conditions
Peripheral Nerve InjurySecondary Raynaud's PhenomenonUlcers Related to Diabetic Foot Syndrome
Phase 1
Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury
NCT02352649
Start: 2015-04-30End: 2017-09-30Target: 45Updated: 2015-02-02
Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
NCT02356809
Start: 2015-03-31End: 2015-08-31Target: 30Updated: 2015-02-05